Ignite Creation Date:
2024-05-06 @ 3:56 PM
Last Modification Date:
2024-10-26 @ 2:00 PM
Study NCT ID:
NCT04814121
Status:
UNKNOWN
Last Update Posted:
2021-03-24
First Post:
2021-02-25
Brief Title:
Suxiao Jiuxin Pills in Microvascular Obstruction in Patients With Acute Coronary Syndrome
Sponsor:
Guangzhou University of Traditional Chinese Medicine
Organization:
Guangzhou University of Traditional Chinese Medicine
Study Overview
Official Title:
Suxiao Jiuxin Pills in Microvascular Obstruction in Patients With Acute Coronary Syndrome
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Microvascular obstruction is the severe complication of percutaneous coronary intervention PCI in patients with acute coronary syndrome Microvascular obstruction after PCI is often association with poor prognosis Current treatments do not show improvement in prognosis of microvascular obstruction Suxiao Jiuxin Pills SXJX was shown associated with a reduction in MACE and an improvement of heart function and quality of life in acute coronary syndrome ACS patients with early PCI To evaluate the effectiveness and safety of SXJX in microvascular obstruction after PCI the investigators designed this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None